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Abstract
Background: The empathogen 3,4-methylenedioxymethamphetamine (MDMA) is the prototypical prosocial club drug 
inducing emotional openness to others. It has recently been shown that acutely applied 3,4-MDMA in fact enhances emotional 
empathy and prosocial behavior, while it simultaneously decreases cognitive empathy. However, the long-term effects of 
3,4-MDMA use on socio-cognitive functions and social interactions have not been investigated yet. Therefore, we examined 
emotional and cognitive empathy, social decision-making, and oxytocin plasma levels in chronic 3,4-MDMA users.
Methods: We tested 38 regular but recently abstinent 3,4-MDMA users and 56 3,4-MDMA-naïve controls with the Movie for 
the Assessment of Social Cognition, the Multifaceted Empathy Test, and the Distribution Game and the Dictator Game. Drug 
use was objectively quantified by 6-month hair analyses. Furthermore, oxytocin plasma levels were determined in smaller 
subgroups (24 3,4-MDMA users, 9 controls).
Results: 3,4-MDMA users showed superior cognitive empathy compared with controls in the Multifaceted Empathy Test 
(Cohen’s d = .39) and in the Movie for the Assessment of Social Cognition (d = .50), but they did not differ from controls in 
emotional empathy. Moreover, 3,4-MDMA users acted less self-serving in the Distribution Game. However, within 3,4-MDMA 
users, multiple regression analyses showed that higher 3,4-MDMA concentrations in hair were associated with lower cognitive 
empathy (βMDMA = -.34, t = -2.12, P < .05). Oxytocin plasma concentrations did not significantly differ between both groups.
Conclusions: We conclude that people with high cognitive empathy abilities and pronounced social motivations might be 
more prone to 3,4-MDMA consumption. In contrast, long-term 3,4-MDMA use might nevertheless have a detrimental effect 
on cognitive empathy capacity.
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Introduction
With an estimated 19.4 million past-year users, 3,4-methylen-
edioxymethamphetamine (MDMA, “ecstasy”) remains one of 
the most used illicit drugs worldwide (United Nations Office 
on Drugs and Crime, 2016). MDMA is a synthetic substituted 
amphetamine derivate that blocks and reverses monoamine 
transporters leading to a rapid release of serotonin (5-HT) and 
noradrenalin and to a lesser extend dopamine (Rudnick and 
Wall, 1992; Kalant, 2001). As its main positive subjective effects 
are enhanced empathy, increased prosocial feelings, and a gen-
eral sense of well-being, MDMA is regarded as the prototypical 
prosocial club drug (Vollenweider et al., 1998; Kamilar-Britt and 
Bedi, 2015). Consequently, in an international survey on drug 
users, MDMA was ranked highest in the condition of sociability 
(Morgan et al., 2013).
In animals, the acute effects of MDMA on social behavior 
have been researched extensively, whereby “adjacent lying” and 
“friendly following” were consistently reported to be increased 
in rats (Ando et al., 2006; Thompson et al., 2009). Together with 
decreased aggression and elevated social reward, literature con-
sistently suggests a prosocial effect profile of MDMA in rodents 
(Kamilar-Britt and Bedi, 2015). Recently, social cognition has 
been broadly investigated in MDMA-challenge studies con-
ducted on healthy human volunteers mostly focusing on meas-
ures of empathy. The concept of empathy has frequently been 
conceptualized as entailing cognitive and emotional compo-
nents. Cognitive empathy, which comprises inferring or discrim-
inating emotions of others together with Theory-of-Mind (ToM), 
which additionally implicates the ability to deduce the perspec-
tive of others, describes the ability to decode and understand 
another person’s mental state (Baron-Cohen and Wheelwright, 
2004; Blair, 2005) on a mere cognitive level without considering 
the person’s emotional response. On the other side, emotional 
empathy is defined as the compassion or the empathizing with 
the emotions of others (Blair, 2005).
Regarding cognitive empathy, acute MDMA intake has 
repeatedly been shown to reduce the identification of negative 
emotional stimuli (Bedi et  al., 2010; Hysek et  al., 2012, 2014a, 
2014b; Kirkpatrick et al., 2014) and one study additionally found 
an increased recognition of positive emotional stimuli (Hysek 
et  al., 2012). These valence-dependent acute MDMA effects 
were—to our knowledge—exclusively found in the Face Emotion 
Recognition Task (Bedi et al., 2010; Hysek et al., 2014b) and the 
Reading the Mind in the Eyes Test (Hysek et al., 2012). In 2 other 
well-established social cognition tasks, namely the Movie for 
the Assessment of Social Cognition (MASC) and the Multifaceted 
Empathy Test (MET), cognitive empathy performance was not 
affected by acute MDMA intake (Kuypers et al., 2017). By contrast, 
emotional empathy ratings— driven by enhanced responses 
to emotionally positively charged stimuli—was shown to be 
increased in the MET under the acute influence of MDMA (Hysek 
et al., 2014b; Schmid et al., 2014). In summary, research on empa-
thy performance suggests that acute MDMA intake decreases 
cognitive empathy but enhances emotional empathy (Kamilar-
Britt and Bedi, 2015), even though these findings are limited 
to specific tasks. Interestingly, these acute prosocial effects of 
MDMA have been linked to central oxytocin (OXT) release, as 
several studies have found dose-dependent increases in blood 
plasma OXT levels right after MDMA administration (Wolff et al., 
2006; Dumont et al., 2009; Hysek et al., 2012; Schmid et al., 2014). 
This increase in plasma OXT levels was shown to correlate with 
increased prosocial feelings in humans (Dumont et al., 2009).
Interestingly, no study has investigated social cognition in 
abstinent, long-term MDMA users to date. Thus, we measured 
cognitive and emotional empathy of relatively pure MDMA users 
and drug-naïve healthy controls with the MASC and the MET. 
To measure social decision-making, we additionally applied 
the Distribution Game and the Dictator Game (Charness and 
Rabin, 2002; Engelmann and Strobel, 2004). Given that acutely 
applied MDMA increases plasma levels of OXT (Dumont et al., 
2009; Hysek et al., 2012) and that a former animal study docu-
mented lasting depletion of brain OXT after long-term MDMA 
administration (van Nieuwenhuijzen et al., 2010), we addition-
ally investigated blood plasma OXT levels in a subsample of our 
participants. Finally, as a special feature of our study, we objec-
tively determined drug use through quantitative hair analy-
ses for several reasons. First, MDMA users often co-use other 
drugs (Schifano et al., 1998; Curran, 2000), and previous MDMA 
research has been criticized for measuring drug consumption 
only via self-reports (Cole, 2014). Second, drug users might be 
motivated to give a biased self-report or simply over- or under-
estimate their own consumption because of consistently shown 
memory alterations (Magura and Kang, 1996; Quednow et  al., 
2006; Wunderli et al., 2017).
Because MDMA has been shown to impair OXT neurotrans-
mission in rats when given chronically (van Nieuwenhuijzen 
et al., 2010) and because OXT and emotional empathy seem to 
be functionally linked (Thompson et al., 2007; Kirkpatrick et al., 
2014), we hypothesized that chronic MDMA users show a deficit 
in emotional empathy and display lowered plasma levels of OXT. 
Alternatively, such deficits could also be preexistent given that 
Significance Statement
Humans show increased empathy under the acute influence of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Even 
in animals, increased prosocial behavior was observed after MDMA application. These prosocial effects of MDMA have been 
proposed to be mediated by an increased oxytocin release. Given that chronic administration of MDMA leads to a long-lasting 
depletion of oxytocin in animal models, it was predicted that MDMA has a detrimental effect on the oxytocin system and con-
sequently on social cognition also in human users. This study therefore investigated the chronic effect of MDMA on social 
cognition and oxytocin in human users. We observed superior cognitive empathy and more prosocial behavior in MDMA users 
compared with MDMA-naïve controls. However, higher MDMA hair concentrations were associated with worse cognitive em-
pathy. We concluded that relatively pure MDMA users are a specific group of socially high-performing drug users but that heavy 
MDMA consumption might lead to decreased cognitive empathy.
Wunderli et al. | 335
the main motivator for MDMA use is to enhance prosocial feel-
ings like feeling closer to other people (Morgan et al., 2013) and 
to increase emotional empathy (Hysek et al., 2014b). Thus, rec-
reational MDMA users might compensate (or self-medicate) a 
deficit in emotional empathy and lower OXT levels by their drug 
intake. Lastly, we expected higher MDMA use to be associated 
with lower cognitive empathy, as it was shown by an inverse 
correlation between lifetime MDMA use and Reading the Mind 
in the Eyes Test performance in one of our previous studies 
(Preller et al., 2014).
Methods
Participants
Within the context of the Zurich Cocaine Cognition Study 
(ZuCo2St) (Vonmoos et al., 2013b; Quednow, 2016), we recruited 
53 long-term MDMA users and 56 MDMA-naïve healthy controls 
by means of online media and flyer advertisements. Candidates 
underwent a standardized telephone screening to assess their 
study eligibility prior to testing. All tested participants were 
aged between 18 and 60 years and had sufficient German lan-
guage skills. We included only MDMA users whose self-reported 
drug use was confirmed by hair analyses and whose MDMA hair 
concentration values exceeded their cocaine and amphetamine 
concentrations—the most common concomitant drugs in our 
sample. Primary stimulant users with only a co-consumption of 
MDMA were thus excluded, as stimulants have been shown to 
strongly affect social cognition (Quednow, 2017). Furthermore, 
because of deficient/missing hair samples, 2 MDMA users were 
excluded. Following this procedure, 38 participants were identi-
fied as MDMA-preferring users and included in the analyses (see 
supplementary Table  1 for detailed hair analyses). The MDMA 
group was matched with 56 MDMA-naïve healthy controls for 
age, sex, verbal intelligence, years of education, depression 
scores, and weekly cannabis consumption (Table 1).
Inclusion criteria for the drug using group were MDMA as 
the primary drug, MDMA use of at least 100 standard doses (one 
MDMA standard dose corresponds to 100 mg crystalline MDMA 
or one ecstasy pill) or weekly consumption during the last year 
( >50 occasions), and a current abstinence period of <6 months. 
Exclusion criteria for the MDMA groups were any acute or pre-
vious Axis-I DSM-IV adult psychiatric disorders with the ex-
ception of MDMA, alcohol, and nicotine abuse and a history of 
depression (acute major depression was excluded). The general 
exclusion criteria encompassed current or previous neurological 
disorders or head injuries, any clinically significant medical dis-
ease, a family history of schizophrenia or bipolar disorder, the 
use of any medication affecting the central nervous system, and 
a lifetime history of opioid use. Additionally, all participants 
who reported daily (or more frequent) cannabis consumption 
were excluded. Controls were also excluded if they fulfilled the 
diagnostic criteria for any Axis-I DSM-IV psychiatric disorder, 
including any form of substance use disorder (except nicotine 
and cannabis) or any other current or previous regular illegal 
drug use.
All participants were asked to abstain from illegal substances 
for at least 3 days and from alcohol for at least 24 hours prior 
to testing. Drug urine screenings were employed to control for 
compliance with the abstinence period (Table 1). The study was 
approved by the Cantonal Ethics Committee of Zurich. All par-
ticipants gave written informed consent and were compensated 
for their participation. Both MDMA users and MDMA-naïve 
healthy controls were already published in Wunderli et al. (2017); 
however, polydrug users with hair concentrations of stimulants 
(e.g., cocaine and amphetamine) exceeding the values of MDMA 
were excluded from the present analysis. Moreover, the present 
MDMA user sample did not overlap with the samples of pre-
vious publications from the ZuCo2St, including cocaine users 
and stimulant-naïve controls (e.g., Preller et  al., 2013, 2014; 
Vonmoos et al., 2013b; Hulka et al., 2014). However, about 75% of 
the present control group has been reported in these previous 
publications, but all participants from the ZuCo2St and the pre-
sent study were investigated with the same procedure in the 
same environment and by the same study team.
Assessment Measures
Clinical Assessment
Trained psychologists conducted the Structured Clinical 
Interview for Axis-I DSM-IV disorders. Depressive symp-
toms were assessed with the Beck Depression Inventory (Beck 
et al., 1961), because depression might impact social cognition 
(Schreiter et  al., 2013) and ADHD symptoms with the ADHD 
Self-Rating Scale (ADHD-SR) corresponding to DSM-IV criteria 
(Rosler et al., 2004) given that ADHD and drug use were shown to 
mutually amplify ToM deficits (Wunderli et al., 2016). Premorbid 
verbal intelligence (verbal IQ) was estimated with a German vo-
cabulary test (Mehrfachwahl-Wortschatz-Intelligenztest) (Lehrl 
et al., 1995). To assess the personality structure of our sample, 
we further applied the Barratt Impulsiveness Scale (BIS-11) 
(Patton et al., 1995) and the Temperament Character Inventory 
(TCI) (Cloninger, 1994).
Drug Use Assessment
Self-reported drug use was assessed with the Interview for 
Psychotropic Drug Consumption (Quednow et  al., 2004). In 
addition, to objectively quantify the severity of participants’ 
drug use during the past months, hair samples were taken 
from the posterior vertex region of the head to determine 
the concentration of 17 common drugs and their metabo-
lites by liquid chromatography-tandem mass spectroscopy. 
To exclude acute intoxication at testing sessions, urine drug 
screenings were employed by semiquantitative enzyme mul-
tiplied immunoassays (for technical details, see supplemen-
tary Methods 1).
Assessment of Empathy and Social Decision-Making
MET
The MET is a computer-based test that consists of 40 pictures of 
people in emotionally charged situations (Dziobek et al., 2008). 
Based on the idea that empathy is a multidimensional construct 
consisting of cognitive and emotional empathy (Davis, 1983), the 
MET requires the participant to deduce the mental state of the 
depicted person by choosing which of 4 words best describes the 
person’s mental state (cognitive empathy) and to indicate his/
her empathic concern (explicit emotional empathy) and arous-
ing rate (implicit emotional empathy) on a rating scale (1–9). To 
avoid multiple testing, we combined (summed up) the implicit 
and explicit emotional empathy measures (for both negative 
and positive stimuli) from the MET to an overall emotional em-
pathy score (Table 2).
MASC
The MASC was developed with the aim to operationalize social 
cognition as close to real life as possible and therefore con-
sists of a 15-minute video that shows 4 characters spending an 
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evening together. The video stops 45 times and questions about 
the characters’ feelings, thoughts, and intentions are asked 
(Dziobek et al., 2006). For each question, 4 different answers are 
presented, whereof one answer represents the correct answer. 
The wrong answers represent 3 different mistakes: (1) instead 
of mentalizing, the subject explained the situation by physical 
causation (no ToM), (2) the subject undermentalized (less ToM), 
and (3) the subject overmentalized (too much ToM). The correct 
number of answers is the main outcome measure of the MASC. 
Additionally, we built the cognitive empathy domain score (CES) 
by averaging the MET cognitive empathy score and the MASC 
sum score after they were z-transformed on the means and 
SDs of the control group to a combined measure of cognitive 
empathy.
Table 1. Demographic Data and Drug Use (Means and SDs)
Controls MDMA Users Value P df
n 56 38
Age, y 25.8 (6.1) 25.9 (6.2) -0.09 .93 92
Years of school education 11.0 (1.6) 10.4 (1.9) 1.7 .10 92
Verbal intelligence 103.9 (8.2) 102.7 (8.3) 0.70 .48 92
BDI score 3.5 (3.8) 4.2 (4.4) -0.73 .47 92
Sex (f/m) 26/30, 46.5 % f 18/20, 47.5% f 0.01 .93 1
Tobacco
Smoking status (y/n)a 41/15, 73.2% y 30/8, 78.9% y 0.40 .53 1
Cigarettes per daya 7.3 (10.1) 7.2 (8.7) 0.01 .99 92
Years of use 6.0 (6.6) 5.3 (5.5) 0.60 .55 92
Alcohol
Status (y/n)a 55/1, 98.2% y 38/0, 100.0% y 0.69 .41 1
Grams per weeka 117.9 (132.0) 151.1 (121.9) -1.2 .22 92
Years of use 8.7 (6.5) 6.3 (6.1) 1.8 .07 92
Cannabis
Status (y/n)a 30/26, 53.5% y 29/9, 76.3% y 5.0 .03 1
Grams per weeka 0.44 (1.0) 0.60 (1.1) -0.67 .51 92
Years of use 3.3 (3.7) 4.7 (5) -1.6 .11 92
Cumulative dose (grams) 195.7 (504.6) 606.8 (1061) -2.5 .01 92
Positive urine testing (n/y)b 48/7, 12,5% y 31/7, 18,4% y 0.57 .45 1
Last consumption (days) 23.1 (32.9), n = 30 17.5 (32.9), n = 29 0.43 .51 57
MDMA
Status (y/n)a 0/56, 0.00% y 38/0, 100.0% y 94.0  <.001 1
Tablets per weeka,c 0.00 (0.00) 0.90 (0.80) - - -
Years of use 0.00 (0.00) 6.7 (6.1) - - -
Cumulative dose (grams) 0.10 (0.40) 229.3 (277.2) -6.2  <.001 92
Last consumption (days) - 25.1 (20.9), n = 38 - - -
Positive urine testing (y/n)b 0/56, 0.00% y 0/38, 0.00% y - - -
Hair analysis pg/mg 0.00 (0.00) 4705 (8521) - - -
Amphetamine
Status (y/n)a 0/56, 0.00% y 22/16, 57.9% y 42.3  <.001 1
Grams per weeka 0.00 (0.00) 0.03 (0.05) - - -
Years of use 0.00 (0.00) 1.9 (2.9) - - -
Last consumption (days) - 29.7 (33.8), n = 22 - - -
Cumulative dose (grams) 0.01 (0.03) 26.5 (107.3) 7.4 .07 92
Positive urine testing (y/n)b 0/56, 0.00% y 0/38, 0.00% y - - -
Hair analysis pg/mge 0.00 (0.00) 192.3 (689.5) - - -
Cocaine
Status (y/n)a 0/56, 0.00% y 20/18, 52,6% y 37.4  <.001 1
Grams per weeka 0.00 (0.00) 0.11 (0.28) - - -
Years of use 0.00 (0.00) 2.3 (3.6) - - -
Last consumption (days) - 29.3 (35.3), n = 20 - - -
Cumulative dose (grams) 0.02 (0.05) 52.3 (150.6) 21.3 .01 92
Positive urine testing (y/n)b 0/55, 0.00% y 1/37, 0.03% y 1.5 .23 1
Hair analysis pg/mg 0.00 (0.00) 578.8 (1344) - - -
BDI, Beck’s Depression Inventory.
Significant P values are shown in bold. Statistical tests: independent t tests for quantitative data, χ2 tests for frequency data. Consumption 
per week, duration of use, and cumulative dose are averages within the total group. Last consumption is an average only for persons who 
reported to have used the drug within the past 6 months. In this case, sample size (n) is shown. One urine sample (control), the ADHD-SR 
data for one participant (MDMA user), the years of scool education for one particant (MDMA user), and the duration of MDMA use for one par-
ticipant were missing.
aDuring the past 6 months.
bFor cutoffs, see supplementary Methods 1.
cIn 100-mg tablets.
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Distribution Game and Dictator Game
The Distribution Game and Dictator Game have been described 
in detail before (Hulka et al., 2014). Notably, in these 2 monetary 
distribution games, the participants actually had the chance 
to gain real money (0.25 Swiss francs per 1 point). In brief, the 
Distribution Game involves 2 players. The participant, every 
time in the position of player A, is requested to choose 1 of 10 
possible point distributions. In the first distribution, both play-
ers receive the same amount of 25 points, which represents the 
only completely fair distribution. In the most unfair distribution, 
player A receives 40 points (Payoff A) and player B only one point 
(Payoff B).
The Dictator Game, which always followed the Distribution 
Game, involved the same 2 players, whereby player A was asked 
to distribute 50 points among himself (Payoff A) and player B 
(Payoff B). In accordance with a previously published paper from 
the ZuCo2St (Hulka et al., 2014), we z-transformed the measures 
of the Distribution and Dictator Game on the means and SD of 
the control group and equally integrated them into the com-
posite Payoff A and Payoff B scores.
For both games, we analyzed Payoff A as the main depend-
ent variable.
Assessment of Blood Plasma OXT Levels
The blood was collected in 5-mL BD Vacutainer K2EDTA tubes 
(Vacutainer Systems, Becton Dickinson) and immediately 
mounted on ice. Right after blood collection, the samples were 
centrifuged at 4000 rpm for 10 minutes at 4°C to separate the 
plasma. After pipetting the plasma, it was stored at -80°C until 
it was analyzed according to procedures employed in previous 
studies (Neumann et al., 2013; Bosch et al., 2015).
Statistical Analysis
We performed the statistical analyses with SPSS 23.0 for 
Windows. Quantitative data were either analyzed by means of 
Student’s t tests (only demographic data), Mann-Whitney tests, 
or 2-way ANCOVA. Frequency data were analyzed by means of 
Pearson’s chi-square tests. We used an alpha level of .05 for all 
statistical tests. In the ANCOVAs applied to compare empathy 
between MDMA users and controls, we introduced group and 
sex as fixed factors, and verbal IQ as a covariate, because it was 
consistently shown that men are less empathic that women 
(Fukushima and Hiraki, 2006; Knickmeyer et  al., 2006; Singer 
et al., 2006; Rueckert and Naybar, 2008) and because verbal IQ 
has been proposed to be linked to empathy measures before 
(Lawrence et al., 2004). Analyzing social decision-making with 
ANCOVAs, sex was used as a second covariate to verbal IQ given 
that age is correlated with prosocial behavior (Hulka et al., 2014). 
We investigated the association between clinical measures 
and empathy and the association between plasma OXT values 
and empathy within MDMA users with correlation analyses 
(Pearson’s product-moment and Spearman’s rank correlation, 
respectively) whereby we applied a significance threshold of 
P < .01 to avoid alpha error accumulation. To be able to assess 
the strength of group differences and their practical significance 
between controls and MDMA users, Cohen’s d effect sizes were 
calculated based on the means and pooled SDs of the 2 groups 
(Cohen, 1988).
To analyze potential cofactors of cognitive empathy, we 
regressed the CES on the demographic variables age, sex, years of 
education, and verbal IQ (forced entry) over all participants and 
over MDMA users only. To analyze drug effects (within MDMA 
users) on cognitive empathy, we regressed CES on the MDMA 
hair analyses while retaining those demographic variables in 
the model that were significantly associated with CES. Because 
our MDMA user group showed, although minimal, co-consump-
tion of other drugs, we additionally added amphetamine and 
cocaine hair analyses together with self-reported measures of 
cannabis, alcohol, and nicotine consumption into the model 
according to previously published investigations of MDMA users 
(Wunderli et al., 2017). Because some of the drug use variables 
displayed a right-skewed distribution, we log-transformed (log10) 
these data after adding the constant 1 to those variables that 
included 0 values.
Based on a posthoc power analysis (after participant’s drug 
use was confirmed by hair analyses) with G*Power 3.1.9.2 (Faul 
et al., 2007), the main effects of the ANCOVAs in this study have 
an alpha-error probability of 5% and a power of 80% (assumed 
6% variance explained by special effect, 24% variance explained 
by the covariates, and 70% error variance). The power analysis 
for our regression model investigating MDMA’s effect on cog-
nitive empathy within MDMA users revealed a power of 80% 
(one-tailed, assumed 13% variance explained by predictor, 12% 
by verbal IQ and 75% residual variance) (Shamay-Tsoory et al., 
2004; Toussaint and Webb, 2005).
Table 2. Emotional and Cognitive Empathy (Means and SEs)
Controls MDMA Users F df, dferr P_group p_IQ p_sex p_group_x_sex
n 56 38
MASC
MASC sum correcta 34.8 (0.43) 36.4 (0.53) 6.0 1, 89 .02 .11 .81 .26
MASC sum no TOM 1.9 (0.23) 1.3 (0.28) 2.5 1, 89 .12 .34 .60 .33
MASC sum less TOM 3.3 (0.28) 3.4 (0.35) 0.03 1, 89 .87 .46 .30 .98
MASC sum too much TOM 5.1 (0.30) 3.9 (0.36) 6.2 1, 89 .01 .36 .08 .36
MET
Emotional Empathy Sum Score (EES) 10.7 (0.31) 10.2 (0.37) 1.2 1, 88 .27 .93 .006 .35
EES over positive pictures 10.3 (0.37) 9.6 (0.45) 1.6 1, 88 .21 .44 .04 .24
EES over negative pictures 11.1 (0.31) 10.8 (0.37) 0.52 1, 88 .47 .46 .003 .65
Cognitive empathy sum scorea 23.8 (0.48) 25.3 (0.57) 3.8 1, 88 .05 .001 .38 .52
CE over positive pictures 12.5 (0.31) 13.6 (0.37) 5.6 1, 88 .02 .002 .23 .05
CE over negative pictures 11.4 (0.36) 11.7 (0.43) 0.35 1, 88 .56 .09 .88 .39
CE, cognitive empathy, MASC, Movie for the assessement of social cognition, MET, Mulftifacetet empathy test.
Significant P values are shown in bold. Statistical test: 2-way ANCOVA with the factors group and sex and the covariate verbal IQ.
aUsed for the cognitive empathy domain score.
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Results
Demographic Characteristics and Drug Use
As intended by the application of our matching procedure, the 
groups did not differ significantly in sex distribution, age, verbal 
IQ, years of education, and depression scores (Table 1). For objec-
tive drug-use measures, the median hair drug concentration for 
the MDMA users (n = 38) was 2116 pg/mg and the middle 50% of 
hair analyses fell between 881 and 3530 pg/mg, whereas none of 
the controls had MDMA in their hair.
Moreover, 26 of the 38 investigated MDMA users showed only 
minimal amphetamine and cocaine hair concentrations below 
the commonly accepted cutoff values (Society of Hair, 2004) of 
200 and 500 pg/mg, respectively (supplementary Table  1). The 
remaining 12 MDMA users displayed amphetamine and/or 
cocaine hair concentrations above the mentioned cutoff values, 
but in each case also showed considerably higher MDMA hair 
concentrations. Therefore, we included all 38 (preferred) MDMA 
users to increase the power of our analyses (for detailed hair 
analyses of all MDMA users, see supplementary Table 1). For self-
reported cannabis parameters, MDMA users did not differ from 
controls for weekly cannabis use during the past half-year, dura-
tion of use, duration since last consumption, and in the amount 
of positive urine analyses. However, MDMA users reported a 
larger lifetime dose of cannabis. Finally, MDMA users did not dif-
fer from controls in any tobacco or alcohol use measures.
Social Cognition
For cognitive empathy, 2-way ANCOVAs revealed a significant 
main effect of group on the CES (d = .62) (Figure 1). Both measures 
constituting the CES also differed between groups, the MASC 
sum score (d = .50) and the MET sum score (d = .39), indicating a 
better cognitive empathy performance of MDMA users compared 
with drug-naïve controls (Table 2). These group differences were 
driven by a superior emotion identification of the MDMA users 
for emotionally positively charged pictures in the MET (d = .47) 
and a reduced tendency to overmentalize (overinterpreted per-
spective-taking) in the MASC (d = .51). A  significant group*sex 
interaction was not found for the MASC sum score, the cognitive 
empathy performance in the MET, or the CES (Table 2).
Regarding emotional empathy (MET), no significant group and 
group*sex interaction effects occurred (P > .24). However, the fac-
tor sex showed a significant impact. As expected, women showed 
higher emotional empathy ratings (d = .58) for positively (d = .43) 
as well as negatively charged pictures (d = .63) (Table 2; Figure 2).
Social Decision-Making
Averaged across the Distribution Game and the Dictator Game, 
MDMA users (mean combined Payoff A = 63.2 ± 13.5 SD) exhib-
ited less self-serving behavior than controls (67.9 ± 14.0) as indi-
cated by a significant difference in the combined score Payoff 
A (F(1,90) = 3.99, P < .05, d = .41). The effect was mainly driven by 
the Distribution Game, in which MDMA users acted less self-
serving (d = .56) (Figure  3). Accordingly, in this game, 53% of 
the MDMA users chose the only fair point distribution (50:50 
for player A and B) as opposed to 25% of the controls (χ2 = 7.50, 
p = .006, φ = .28).
Clinical Measures
MDMA users reported significantly more ADHD symptoms 
than controls (d = .66) (Table 3). In the BIS-11, the MDMA users 
displayed higher trait impulsivity (total score) compared with 
controls (d = .53). Likewise, significant main group effects were 
found for the subscales attentional impulsiveness (d = .41) and 
non-planning impulsiveness (d = .47). In the TCI, MDMA users 
differed from controls in novelty seeking (NS) scores (d = .57), 
driven by the subscore disorderliness (NS4) (d = .52) (Table 3). 
Correlation analyses showed that severity of ADHD symptoms 
correlated significantly with BIS-11 attentional impulsiveness 
but not with TCI NS and NS4 scores. Finally, the BIS-11 total 
score was robustly correlated with TCI NS score (supplementary 
Table 2).
Regression Models
To analyze potential cofactors on cognitive empathy, we 
regressed the CES on demographic variables (age, sex, years 
of education, and verbal IQ). This analysis over all participants 
(n = 94) revealed significance for the verbal IQ coefficient (β = .344, 
t = 3.31, P < .001) only (supplementary Table 3). In a second step, 
we additionally introduced a grouping variable (MDMA users vs 
controls) into the model. This grouping variable significantly pre-
dicted cognitive empathy (β = .301, t = 3.11, P < .01). The amount 
of explained variance (corrected) increased significantly (P < .01) 
from 9% in the model without the grouping variable to 17% in 
the model with the grouping variable (R2corr = 0.17, F5,87 = 4.70, 
P < .001).
Within MDMA users (n = 38), again, verbal IQ was the only 
demographic variable significantly associated with cognitive 
empathy (β = .408, t = 2.33, P < .05). To analyze the effect of MDMA 
on cognitive empathy, we therefore regressed the CES on the 
MDMA hair analysis and the verbal IQ score. Interestingly, of the 
2 predictors, only higher MDMA hair concentration significantly 
Figure 1. Differences in a combined cognitive empathy score between controls 
(n = 56) and 3,4-methylenedioxymethamphetamine (MDMA) users (n = 37). 
Estimated means and SEs of the cognitive empathy domain score (CES). *P < .05.
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predicted lower cognitive empathy (β = -.324, t = -2.13, P < .05) 
(Figure  4; supplementary Table  4). Consequently, we excluded 
verbal IQ in a second step. The change in F was nonsignificant 
(P = .09). In a third step, we added amphetamine and cocaine hair 
concentration values, self-reported lifetime cannabis consump-
tion (in grams), as well as the duration of alcohol and nicotine 
consumption into the model. Because no objective measures 
were available for cannabis, alcohol, and nicotine consumption, 
self-reported variables were used to operationalize the influ-
ence of these substances. Importantly, the amount of explained 
variance did not increase (P = .60) by adding these drugs into the 
model, and none of the coefficients predicted cognitive empathy 
except for MDMA (P < .05). In conclusion, group differences in 
cognitive empathy cannot be explained, for example, by the 
co-use of stimulants of the MDMA users. Finally, MDMA hair 
concentration predicted neither emotional empathy nor proso-
cial behavior in MDMA users (β = .194, t = .947, P = .35 and β = .251, 
t = 1.008, P = .32, respectively).
Oxytocin and Empathy
Blood plasma OXT levels were available for 9 controls and 24 
MDMA users only. A  Mann-Whitney test indicated no group 
difference in blood plasma OXT levels between controls (me-
dian = 13.56 pg/mL) and MDMA users (median = 18.29 pg/mL), 
even though MDMA users unexpectedly showed moderately 
higher levels (U = 139.0, P = .22, d = .42) (Figure  5). Within the 
MDMA users, blood plasma OXT levels did not correlate signifi-
cantly with any MDMA use parameters. Moreover, women’s OXT 
levels were ranked higher than those of men (rs = -.35, P < .05). 
Finally, in accordance with the gender effects on both emotional 
empathy and OXT plasma concentrations, we found that higher 
OXT levels were positively correlated with higher emotional em-
pathy (rs = .44, P < .03) in MDMA users.
Discussion
The aim of the study was to investigate empathy and social 
decision-making in objectively verified long-term MDMA users 
taking this drug as their main drug of choice. Detailed psychiat-
ric diagnostics, hair toxicology, and matching were used to min-
imize the influence of psychiatric comorbidities and polydrug 
use. We showed that MDMA users display superior cognitive 
empathy compared with MDMA- and stimulant-naïve healthy 
controls on one hand but that within MDMA users, increased 
MDMA hair contamination is associated with a decrease in cog-
nitive empathy on the other hand. Additionally, MDMA users 
acted more pro-social than controls in the social decision-
making tasks. Finally, the OXT system is likely not affected 
after long-term MDMA consumption, as peripheral OXY plasma 
levels were not significantly changed even though moderately 
elevated (d = 0.42). In sum, these data suggest that recreational 
long-term MDMA users do not compensate for emotional empa-
thy deficits by consuming MDMA (as no deficit was found), but 
rather show better cognitive empathy and pronounced prosocial 
behavior.
Figure 2. Differences in emotional empathy between women (n = 43) and men (n = 50). Estimated means and SEs of emotional empathy ratings for all emotionally 
charged pictures, emotionally positively charged pictures, and emotionally negatively charged pictures. *P < .05, **P < .01.
Figure  3. Differences in self-serving behavior between controls (n = 56) and 
3,4-methylenedioxymethamphetamine (MDMA) users (n = 38). Estimated means 
and SEs of the z-transformed payoff A (points participants gave to themselves) 
in the Distribution game and the Dictator game. **P < .01.
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In line with previous studies investigating MDMA and stim-
ulant users in general (Morgan, 1998; Butler and Montgomery, 
2004; Vonmoos et al., 2014), our sample of main MDMA users 
showed increased trait impulsivity (BIS-11) together with higher 
novelty seeking scores (TCI) compared with drug-naïve con-
trols. This characterizes our sample of MDMA users as a typical 
recreational drug user sample as proposed before (Rounsaville, 
2004; Vonmoos et  al., 2013a; Maier et  al., 2015). However, our 
sample of MDMA users might be special given that it encom-
passes 26 relatively pure and stimulant-free MDMA users 
(Table  1). Thus, our findings of a superior cognitive empathy 
and prosocial behavior in MDMA users might be valid only for 
relatively pure MDMA users and not for the more typical type of 
polydrug MDMA users (Schifano et al., 1998). Moreover, cogni-
tive empathy and prosocial behavior were not correlated with 
ADHD symptoms, impulsivity, and novelty seeking (supplemen-
tary Table 2). Thus, our finding of superior cognitive empathy 
and prosocial behavior cannot be explained by elevated impul-
sivity and novelty-seeking in MDMA users. Interestingly, the 
higher cognitive empathy of the MDMA users in this study were 
mainly driven by a superior identification of positive emotions 
in the MET compared with controls. Therefore, one might con-
clude that either MDMA chronically induces a “positivity bias” 
with regard to cognitive empathy or that people with a predis-
posed emotional “positivity bias” prefer MDMA as a recreational 
drug. In line with our findings, Hysek et al. (2012) showed that 
MDMA acutely enhances the ability to interpret stimuli with 
positive emotional valence correctly. Moreover, also the emo-
tional empathy for positive stimuli is increased acutely (Hysek 
et al., 2014b). Thus, the valence of emotional stimuli is of criti-
cal importance when considering acute and chronic effects of 
MDMA on measures of empathy.
Using the same test battery, we have previously shown that 
relatively pure recreational and addicted cocaine users show 
impaired cognitive empathy (Hulka et al., 2013) and emotional 
empathy (Preller et  al., 2014), which stands in strong contrast 
to the findings in MDMA users presented here. Hence, although 
their personality traits (impulsivity and novelty seeking) resem-
ble those of stimulant users, the group of relatively pure MDMA 
users seems to be a unique group of socially high-performing 
drug users. This notion is further supported by our results 
regarding social decision-making as MDMA users, which, con-
trary to cocaine users (Hulka et al., 2014), acted more prosocial 
in the neuroeconomic games compared with controls. If this 
increased prosocial behavior of the MDMA users is a preexist-
ing trait or rather a consequence of regular MDMA consumption 
cannot be explained by a cross-sectional study as the present 
one. Nevertheless, it seems plausible that repeated experienc-
ing of interpersonal closeness leads to more prosocial behavior. 
Moreover, together with emotional empathy (empathic concern 
for others), cognitive empathy (mental and emotional perspec-
tive-taking) has previously been shown to correlate with affili-
ation motivation (Hill, 1987). More specifically, the underlying 
Table 3. Clinical Measures
Controls MDMA F df, dferr P
n 56 38
ADHD self-report rating scale (ADHD-SR)
ADHD-SR sum score 7.7 (0.8) 12.0 (1.0) 10.7 1, 88 .001
Barratt Impulsiveness Scale (BIS-11)
BIS-11 total score 62.0 (1.2) 66.8 (1.4) 6.5 1,89 .01
 FI attentional impulsiveness 14.3 (0.4) 15.6 (0.5) 4.0 1,89 .05
 FII motor impulsiveness 21.9 (0.5) 23.2 (0.6) 2.9 1,89 .09
 FIII nonplanning impulsiveness 25.9 (0.6) 28.0 (0.7) 4.8 1,89 .03
Temperament and Character Inventory
Self-directedness 33.8 (0.77) 32.4 (0.93) 1.4 1, 88 .24
Cooperativeness 33.5 (0.69) 32.2 (0.83) 1.4 1, 88 .23
Self-transcendence 10.8 (0.82) 12.1 (0.98) 0.92 1, 88 .34
Harm avoidance 12.8 (0.76) 11.2 (0.91) 2.0 1, 88 .16
Reward dependence 17.1 (0.48) 15.9 (0.58) 2.6 1, 88 .11
Persistence 4.0 (0.28) 3.2 (0.33) 3.3 1, 88 .07
Novelty seeking total score (NS) 22.3 (0.69) 25.4 (0.83) 7.8 1, 88 .007
 NS1 exploratory excitability 7.8 (0.27) 8.5 (0.32) 2.6 1, 88 .11
 NS2 impulsiveness 4.4 (0.32) 5.3 (0.38) 2.7 1, 88 .11
 NS3 extravagance 5.7 (0.27) 6.3 (0.32) 1.7 1, 88 .20
 NS4 disorderliness 4.3 (0.25) 5.3 (0.3) 6.3 1, 88 .01
Estimated means and SEs. 2-way ANCOVA (verbal IQ score as covariate, group, and sex as factors). The ADHD-SR data for one participant 
(MDMA user) are missing. Significant P values are shown in bold.
Figure 4. Regression of cognitive empathy on 3,4-methylenedioxymethamphet-
amine (MDMA) hair concentrations (pg/mg). Regression of the CES z-score on the 
MDMA hair concentrations (log10) of the MDMA users (n = 38), r(36) = -.34, P <  .05, 
2-way. Higher hair values were associated with lower cognitive empathy.
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dimensions of positive stimulation, the tendency to receive 
gratification from harmonious relationships and from a sense 
of communion (Hill, 1987), correlated highest with cognitive 
empathy. Thus, it seems likely that MDMA users display high 
affiliation motivation and that they use MDMA in social environ-
ments to satisfy this need for affiliation by MDMA’s acute effect 
of enhanced emotional empathy (Hysek et al., 2014b).
The results of the regression analysis for demographic vari-
ables emphasize our finding of superior cognitive empathy in 
MDMA users in 2 ways: first, the group contrast remains signifi-
cant, even when the variables age and years of school education 
are held constant in addition to verbal IQ and sex. Second, al-
most one-half of the explained variance in cognitive empathy 
is explained by the group contrast. Notably, within MDMA users, 
our regression model was most efficient when only the hair 
toxicology analysis of MDMA was entered into the model, indi-
cating a possible detrimental chronic effect of MDMA on social 
cognition as it was predicted from animal studies before (Boot 
et  al., 2000; McGregor et  al., 2008; van Nieuwenhuijzen et  al., 
2010). We are aware that causal interpretations of drug effects 
derived from a cross-sectional investigation are speculative. 
Nevertheless, the present results are in line with earlier studies 
from our group showing dose-dependent impairment of execu-
tive functions in MDMA users (Quednow et al., 2006, 2007). In 
fact, cognitive empathy has been shown to correlate with execu-
tive functioning before (Eslinger et al., 2011) and in our sample, 
a domain score of executive functions, according to Vonmoos 
et al. (2013b) and Wunderli et al. (2016), was positively correlated 
with the MASC sum score (r(92) = .227, P < .05). Additionally, low 
recall consistency, as a measure for executive functioning, has 
been correlated with decreased glucose metabolism in the right 
dorsolateral prefrontal cortex in MDMA users in a recent PET 
study (Bosch et  al., 2013). Given that adaptations in serotonin 
transporter density (McCann et al., 1998; Kish et al., 2010) as well 
as 5HT2A receptor density (Reneman et al., 2002) in the prefrontal 
cortex have been reported in MDMA users, changes in the pre-
frontal 5HT system might be responsible for the demonstrated 
decrease in cognitive empathy that went along with increased 
MDMA hair concentrations. Finally, it would be interesting to in-
vestigate cognitive empathy in an MDMA user sample in a longi-
tudinal study in which premorbid cognitive empathy scores are 
gathered and empathy scores together with sustained drug use 
are measured over time to answer the question if the changes 
shown here are predisposed or MDMA-induced.
This study has some limitations. First, the common practice 
to measure drug use by means of self-reported drug assess-
ments has been criticized before (Cole, 2014). Therefore, we ob-
jectively quantified our participants’ drug use via hair toxicology 
analyses but still had to rely on self-reports for alcohol, nicotine, 
and cannabis consumption. Being aware of this problem, we 
aimed to minimize the influence of these drugs by matching the 
groups accordingly. Second, we cannot rule out that the superior 
cognitive empathy of MDMA users is in fact a consequence at 
least of light or moderate MDMA consumption. Likewise, the 
implicated detrimental effect of MDMA on cognitive empathy is 
based only on the correlation between past drug use (hair analy-
ses) across the last 3 to 6 months and current cognitive empathy. 
We therefore suggest that future research investigates this re-
lationship in a longitudinal study. Third, our sample comprises 
26 stimulant-free, pure MDMA users and might therefore not be 
generalizable to the prototypical recreational polydrug MDMA 
user. Fourth, our exploratory investigation of blood plasma 
OXT is based on a rather small sample size (n = 24 users vs n = 9 
controls). Moreover, peripheral OXT levels might not reflect 
the status of the neural OXY system (Kagerbauer et al., 2013). 
Therefore, the possibility of a long-term MDMA consumption 
effect on neural OXT systems still cannot be ruled out. We sug-
gest that blood plasma OXT values of long-term MDMA users 
are compared with MDMA-naïve controls in a bigger sample in 
which sex is distributed evenly between groups. Moreover, an 
OXY receptor radioligand should be developed to investigate the 
status of the cerebral OXY system in human MDMA users by 
positron emission tomography.
Taken together, our data suggest that primary MDMA users 
show personality traits comparable with recreational stimulant 
users, but in contrast to those show superior cognitive empathy 
and more pro-social behavior than drug-naïve, healthy controls. 
Primary MDMA users might therefore be described as socially 
high performing drug users. However, because severe chronic 
MDMA consumption seems to have a toxic effect on cognitive 
empathy, we suggest that the superior cognitive empathy of 
MDMA users is not a consequence of MDMA use, but rather a 
predisposition for it. We conclude that main MDMA users do 
not consume MDMA to compensate for emotional empathy 
deficits but are more prone to MDMA consumption because 
of pronounced cognitive empathy likely going along with high 
affiliation motivation.
Supplementary Material
Supplementary data are available at International Journal of 
Neuropsychopharmacology online.
Figure 5. Mean peripheral blood plasma oxytocin (OXT) levels (pg/mL) of controls 
(n = 9) and 3,4-methylenedioxymethamphetamine (MDMA) users (n = 24). Groups 
did not differ signifianctly (P > .05, d = .42). Circles represent female and dots rep-
resent male participants.
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